UnitedHealth Group CEO Andrew Witty, during the company’s first earnings call since the death of executive Brian Thompson, criticized the U.S. healthcare system’s complexity and high costs, driven by a profit-focused model where high costs benefit many participants. Witty specifically cited discrepancies in drug pricing, blaming pharmaceutical companies while asserting UnitedHealth’s efforts to improve transparency. Despite record 2024 revenues, the company reported worse-than-expected quarterly results, and Witty reaffirmed the company’s commitment to improving the system.
Read More
Due to resolved shortages of Eli Lilly’s weight-loss and diabetes medications, Zepbound and Mounjaro, the FDA has ordered a phase-out of copycat versions sold by specialty and online pharmacies. This decision, effective within 60-90 days, benefits Lilly and potentially impacts patient access and costs. The FDA cited improved supply and safety concerns regarding the compounded drugs as reasons for the action. This reversal follows an earlier decision that was met with public opposition and legal challenge.
Read More
New York’s Governor Hochul has signed into law S.7114-A/A.6425-A, capping out-of-pocket expenses for EpiPens at $100 for consumers with commercial insurance. This addresses the dramatic price increases of EpiPens, which have risen over 600% since 2007, making this life-saving medication more accessible. The legislation mandates coverage for EpiPens by all health insurers in both individual and group markets, ensuring equitable access to emergency treatment for anaphylaxis. This action prioritizes public health by mitigating the financial burden associated with this essential medication.
Read More
As a Canadian, I am elated to hear the news that the government has passed a bill to cover the costs of birth control and diabetes drugs for all citizens. This is a monumental step towards ensuring that essential healthcare needs are met for all Canadians, regardless of their financial situation. The fact that paying for prevention is far cheaper than treating illness from a budgetary standpoint is a crucial point to consider. By covering these costs upfront, the government is not only promoting public health but also potentially saving money in the long run.
It is heartwarming to see a piece of news that aligns with our national values and makes us feel proud to be Canadian.… Continue reading
As a healthcare professional, I have always been appalled by the exorbitant prices that pharmaceutical companies charge for life-saving medications in the United States. The recent controversy surrounding Novo Nordisk’s pricing of Ozempic and Wegovy sheds light on the profit-driven motives that underlie the pharmaceutical industry. It is truly disheartening to see medications that could potentially improve the health and well-being of individuals being priced out of reach for many Americans.
Novo Nordisk’s CEO, Lars Fruergaard Jørgensen, has defended the high U.S. prices of these drugs by claiming that they are ‘helping’ reduce the cost of obesity in the long run.… Continue reading
I find it truly remarkable that a potential breakthrough in HIV prevention is within reach, with a vaccine that could cost as little as $40 a year per patient. The introduction of lenacapavir, an injection that can prevent infection and suppress HIV, is indeed a significant step forward in the fight against this global health crisis. The prospect of having an injection that only needs to be administered every six months and can provide such crucial protection is a game-changer. It is something that could potentially revolutionize the way we approach HIV prevention.
However, the reality of the situation quickly becomes grim when we realize that the actual cost of taking this vaccine in the USA is staggering.… Continue reading
John Q. Hosedrinker